ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08808
0,06%
Bitcoin
67.053,65
1,18%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Deutschland
  5. TG
  6. Genmab AS (GE9)

  7. Genmab AS (GE9) News

GE9 Genmab AS

275,60
2,50 (0,92%)
17 Mai 2024 - Geschlossen
Echtzeitdaten
Name Symbol Markt Aktientyp
Genmab AS GE9 Tradegate Ordinary Share
  Änderung Änderung % Aktuell Zeit
2,50 0,92% 275,60 23:50:06
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
273,90 272,00 273,90 275,60 273,10
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
14.5.202416:02GLOBEGenmab to Present New and Updated Results From Multiple..
13.5.202416:09GLOBETransactions in Connection with Share Buy-back Program
07.5.202420:27GLOBECapital Increase in Genmab as a Result of Employee Warrant..
06.5.202416:01GLOBETransactions in Connection with Share Buy-back Program
02.5.202417:01GLOBEGenmab Announces Financial Results for the First Quarter of..
30.4.202400:40GLOBETIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval..
29.4.202410:24GLOBETransactions in Connection with Share Buy-back Program..
22.4.202409:30GLOBETransactions in Connection with Share Buy-back Program..
16.4.202412:24GLOBEGenmab Announces Net Sales of DARZALEX® (daratumumab) for..
15.4.202410:07GLOBETransactions in Connection with Share Buy-back Program..
08.4.202411:44GLOBETransactions in Connection with Share Buy-back Program
03.4.202407:34GLOBEGenmab to Broaden and Strengthen Oncology Portfolio with..
02.4.202409:24GLOBETransactions in Connection with Share Buy-back Program
25.3.202414:30GLOBETransactions in Connection with Share Buy-back Program
18.3.202410:49GLOBECompletion of share buy-back program
15.3.202413:16GLOBEGenmab Announces Initiation of Share Buy-Back Program
13.3.202421:58GLOBETransactions with shares and linked securities in Genmab A/S..
13.3.202421:52GLOBEConstitution of the Board of Directors in Genmab A/S, Grant..
13.3.202416:13GLOBEPassing of Genmab A/S’ Annual General Meeting
11.3.202410:42GLOBETransactions in connection with share buy-back program
04.3.202419:10GLOBETransactions with shares and linked securities in Genmab A/S..
04.3.202410:29GLOBETransactions in connection with share buy-back program
02.3.202400:04GLOBETransactions with shares and linked securities in Genmab A/S..
29.2.202416:48GLOBETransactions with shares and linked securities in Genmab A/S..
27.2.202421:42GLOBETransactions with shares and linked securities in Genmab A/S..
27.2.202421:40GLOBECapital Increase in Genmab as a Result of Employee Warrant..
27.2.202401:45GLOBEU.S. FDA Accepts for Priority Review the Supplemental..
26.2.202411:21GLOBETransactions in connection with share buy-back program
23.2.202423:50GLOBETransactions with shares and linked securities in Genmab A/S..
23.2.202423:35GLOBEGrant of Restricted Stock Units to Management and Employees..
19.2.202410:40GLOBETransactions in connection with share buy-back program
15.2.202412:00GLOBENotice to Convene the Annual General Meeting of Genmab A/S
14.2.202420:09GLOBEGenmab Files Annual Report with the U.S. Securities and..
14.2.202417:41GLOBEGenmab Announces Initiation of Share Buy-Back Program
14.2.202417:02GLOBEGenmab Publishes 2023 Annual Report
02.2.202412:45GLOBETisotumab Vedotin Marketing Authorization Application..
25.1.202420:22GLOBEGrant of Restricted Stock Units and Warrants to Employees in..
23.1.202412:24GLOBEGenmab Announces Net Sales of DARZALEX® (daratumumab) for..
23.1.202400:40GLOBEGenmab Announces Decision in Arbitration Appeal under..
09.1.202412:45GLOBETIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics..
03.1.202406:55GLOBETransactions With Shares and Linked Securities in Genmab A/S..
02.1.202415:52GLOBEGenmab to Present at the 42nd Annual J.P. Morgan Healthcare..
12.12.202313:00GLOBEGenmab to Hold 2023 R&D Update and ASH Data Review Meeting
09.12.202318:00GLOBENew Pivotal Data for Bispecific Antibody Epcoritamab..
05.12.202323:26GLOBECapital Increase in Genmab as a Result of Employee Warrant..
27.11.202313:00GLOBEGenmab Announces Positive Regulatory Updates for Epcoritamab..
21.11.202322:45GLOBETransactions with shares and linked securities in Genmab A/S..
21.11.202322:42GLOBEGrant of Restricted Stock Units to Board Members and..
09.11.202315:14GLOBEMajor Shareholder Announcement
09.11.202311:00GLOBEGenmab to Present at Jefferies London Healthcare Conference

Kürzlich von Ihnen besucht

TG
GE9
Genmab AS
NYSE
AHLT
American Beacon
COIN
BYTEEETH
BYTNODE
TG
ZM5P
CMC Metals
BIT
UB9P72
Unicredit Bank
NASDAQ
GGMCU
Glenfarne Merger
NASDAQ
KRRO
Korro Bio
COIN
PLUGBP
Pluton
TG
1WM
Consolidated Uranium
TG
CHO
Conduit
TG
KT31
Golden Ocean
TG
34Q0
Quantum eMotion
NASDAQ
CRMLW
Critical Metals
TSX
5577
Aidemy
TG
3GD
Beneteau
COIN
PKRETH
POLKER
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten